Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) FCF Margin (2017 - 2025)

Autolus Therapeutics' FCF Margin history spans 5 years, with the latest figure at 199.91% for Q4 2025.

  • For Q4 2025, FCF Margin rose 9898629.0% year-over-year to 199.91%; the TTM value through Dec 2025 reached 377.69%, up 167646.0%, while the annual FY2025 figure was 377.69%, 167828.0% up from the prior year.
  • FCF Margin reached 199.91% in Q4 2025 per AUTL's latest filing, up from 341.17% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 199.91% in Q4 2025 to a low of 99186.21% in Q4 2024.
  • Average FCF Margin over 3 years is 14587.76%, with a median of 669.84% recorded in 2024.
  • The largest YoY upside for FCF Margin was 9898629bps in 2025 against a maximum downside of -52644bps in 2025.
  • A 3-year view of FCF Margin shows it stood at 11683.5% in 2023, then plummeted by -749bps to 99186.21% in 2024, then surged by 100bps to 199.91% in 2025.
  • Per Business Quant, the three most recent readings for AUTL's FCF Margin are 199.91% (Q4 2025), 341.17% (Q3 2025), and 382.63% (Q2 2025).